Quantitative tool for rapid disease mapping using optical coherence tomography images of azoxymethane-treated mouse colon.
Optical coherence tomography (OCT) can provide new insight into disease progression and therapy by enabling nondestructive, serial imaging of in vivo cancer models. In previous studies, we have shown the utility of endoscopic OCT for identifying adenomas in the azoxymethane-treated mouse model of colorectal cancer and tracking disease progression over time. Because of improved imaging speed made possible through Fourier domain imaging, three-dimensional imaging of the entire mouse colon is possible. Increased amounts of data can facilitate more accurate classification of tissue but require more time on the part of the researcher to sift through and identify relevant data. We present quantitative software for automatically identifying potentially diseased areas that can be used to create a two-dimensional "disease map" from a three-dimensional Fourier domain OCT data set. In addition to sensing inherent changes in tissue that occur during disease development, the algorithm is sensitive to exogeneous highly scattering gold nanoshells that can be targeted to disease biomarkers. The results of the algorithm were compared to histological diagnosis. The algorithm was then used to assess the ability of gold nanoshells targeted to epidermal growth factor receptor in vivo to enable functional OCT imaging.
Winkler
Amy M
AM
University of Arizona, College of Optical Sciences, Tucson, Arizona 85721-0240, USA. awinkler@optics.arizona.edu
Rice
Photini F S
PF
Drezek
Rebekah A
RA
Barton
Jennifer K
JK
D000465:Algorithms; D000818:Animals; D001397:Azoxymethane; D003110:Colonic Neoplasms / Q000473:pathology*; D007089:Image Enhancement / Q000379:methods; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D021621:Imaging, Three-Dimensional / Q000379:methods*; D051379:Mice; D010363:Pattern Recognition, Automated / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012984:Software; D041623:Tomography, Optical Coherence / Q000379:methods*
D001397:Azoxymethane
Nano Lett. 2005 Apr;5(4):709-11
15826113
Gastrointest Endosc. 2003 Aug;58(2):196-202
12872085
Cancer Biol Ther. 2007 Nov;6(11):1753-62
17986850
Opt Lett. 2001 Jul 1;26(13):992-4
18040511
Phys Med Biol. 2006 Aug 21;51(16):3885-900
16885613
J Biomed Opt. 2005 Nov-Dec;10(6):064024
16409089
Lasers Med Sci. 2009 Jul;24(4):627-38
18936871
Lasers Surg Med. 2007 Oct;39(9):687-95
17960754
J Biomed Opt. 2006 Jul-Aug;11(4):044010
16965167
J Biomed Opt. 2006 Jul-Aug;11(4):041121
16965149
Endoscopy. 2000 Oct;32(10):743-9
11068832
Opt Lett. 2005 May 1;30(9):1012-4
15906987
Endoscopy. 2000 Oct;32(10):750-5
11068833
Toxicol Sci. 2005 Dec;88(2):340-5
16150884
Gastrointest Endosc Clin N Am. 2004 Jul;14(3):555-71, x
15261202
J Biomed Opt. 2006 Nov-Dec;11(6):064003
17212526
J Biomed Opt. 2003 Jul;8(3):484-94
12880355
Science. 1997 Jun 27;276(5321):2037-9
9197265
J Biomed Opt. 2005 Nov-Dec;10(6):064035
16409100
Clin Gastroenterol Hepatol. 2006 Jan;4(1):38-43
16431303
Endoscopy. 2007 Jul;39(7):599-605
17611914
IEEE Trans Med Imaging. 2005 Oct;24(10):1369-76
16229422
Opt Express. 2009 Jan 19;17(2):784-96
19158891
Endoscopy. 2000 Oct;32(10):796-803
11068841
J Biomed Opt. 2009 Sep-Oct;14(5):054015
19895117
Opt Express. 2008 Jun 9;16(12):8406-20
18545554
Opt Express. 2004 Jul 26;12(15):3532-42
19483882
J Biomed Opt. 2008 Sep-Oct;13(5):054055
19021435
J Biomed Opt. 1999 Jan;4(1):95-105
23015175
Phys Med Biol. 2008 Dec 7;53(23):6767-75
18997266
Cancer Biomark. 2006;2(3-4):163-73
17192069
Nat Med. 1995 Sep;1(9):970-2
7585229